Thambisetty, Madhav;
Howard, Robert;
(2023)
Lecanemab and APOE Genotyping in Clinical Practice-Navigating Uncharted Terrain.
JAMA Neurology
, 80
(5)
pp. 431-432.
10.1001/jamaneurol.2023.0207.
Preview |
Text
Howard_Lecanemab and APOE genotyping in clinical practice navigating uncharted terrain R1_mark upRH_Jan 15 2023.pdf Download (169kB) | Preview |
Abstract
Publication of results from the phase 3 Lecanemab for People with Early Alzheimer's Disease (Clarity AD) trial, with demonstration that the drug provided a small clinical benefit and may have slowed disease progression, has brought hope to millions of patients with Alzheimer disease (AD) and their families around the world.1 The US Food and Drug Administration (FDA) recently approved lecanemab for treating patients in early stages of AD. Analyses of Clarity AD results have already spurred passionate debate about the meaningfulness of clinical benefits observed and whether, after consideration of associated risk of adverse events, the drug represents a truly effective and safe treatment.
Archive Staff Only
 |
View Item |
